Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Hodgkin LymphomaLymphoma
Interventions
DRUG

Bortezomib

1.0 mg/m\^2 by Vein Over 5 Seconds on Days 1 and 4

DRUG

Carboplatin

5 AUC by Vein Over 1 Hour On Day 1

DRUG

Etoposide

100 mg/m\^2 By Vein Over 2 Hours On Days 1-3

DRUG

Ifosfamide

5 Gm/m\^2 By Vein Continuous Infusion Over 24 Hours On Day 1

DRUG

Mesna

5 mg/m\^2 IV continuous Infusion over 24 Hours On Day 1; 2 Gm/m\^2 IV continuous infusion over 12 hours starting after completion of Ifosfamide + Mesna 24 hour continuous infusion

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER